INTRODUCTION: Cirrhosis due to nonalcoholic fatty liver disease (NAFLD) is a growing problem, contributing to increasing health care burden. The most effective weight loss intervention is bariatric surgery, but there is little data on ability of medical centers to safely conduct bariatric surgery in this population. We investigated the safety, efficacy, and outcomes of patients with cirrhosis receiving surgery, compared to those without cirrhosis at our medical center. METHODS: We performed a historical cohort study of patients with a diagnosis of cirrhosis undergoing bariatric surgery at Yale-New Haven Hospital. We identified cases through electronic query of patients receiving surgery between 2014 and 2017, with diagnosis codes of cirrhosis. Controls were matched in a 2:1 ratio, by surgery time period. Patient demographic, baseline liver-related and metabolic data, and perioperative outcomes were obtained at time of surgery. Metabolic and liver-related outcomes were assessed at 3 years after surgery. RESULTS: A total of 52 patients were included (18 with cirrhosis, 34 without cirrhosis) (Table 1). Perioperatively, 3 patients with cirrhosis developed bleeding compared to none of the non-cirrhotic patients (P = 0.03). Bleeding was self-limited and did not require surgical intervention or blood transfusion. There were no cases of post-operative infection, leak, revision surgery, nor deaths. Median length of stay was 2 days in both groups. Over 3 years, serum ALT significantly improved in patients with cirrhosis (−13.3 ± 5.1 U/L, P = 0.01). Average MELD and Child-Pugh scores did not worsen over 3 years, and MELD score trended towards improvement (−0.75 ± 0.4 points, P = 0.08). Significant decreases in body weight (−16.4 ± 2.8 kg, P < 0.0001), body mass index (BMI) (−6.1 ± 1.0 kg/m2, P < 0.0001) were observed in those with cirrhosis. There was a trend towards decreased mean glycosylated hemoglobin (−0.9 ± 0.7%, P = 0.20) and total cholesterol (−29.6 ± 19.2 mg/dL, P = 0.18) (Figure 1). CONCLUSION: Bariatric surgery is safe in patients with cirrhosis at our medical center. For patients with metabolic liver disease such as NAFLD, surgery holds promise even after the development of cirrhosis. Further study is needed to develop criteria which will identify patients with cirrhosis who can safely undergo surgery. This will likely be coupled with the development of destination centers which can safely carry out surgery in such high-risk patients and link to further clinical resources.Table 1.: Baseline Characteristics of Patients with and Without Cirrhosis Undergoing Bariatric Surgery.Figure 1.: 3-Year Change in Liver-Related and Metabolic Parameters in Patients with Cirrhosis Receiving Bariatric Surgery.